Tivic Health Systems, INC Schedule 13D activist filings

3i, LP reports an increase in beneficial ownership of Valion Bio, Inc. common stock to 9.9%, primarily through warrant exercises and convertible note/preferred stock conversions, subject to beneficial ownership limitations.

Valion Bio, Inc. files Amendment No. 6 to Schedule 13D, detailing a significant transaction by 3i, LP involving preferred stock, warrants, and a convertible note.

Valion Bio, Inc. has filed an amendment to its Schedule 13D, with 3i LP reporting a minor purchase of common stock and detailing its beneficial ownership structure.

3i LP has amended its Schedule 13D filing to report recent transactions, including the sale of common stock and conversions of Series C Preferred Stock, impacting its beneficial ownership in Valion Bio, Inc.

3i LP has sold a substantial number of Valion Bio, Inc. shares and is in ongoing funding negotiations, signaling potential financial pressures.

An amendment to a Schedule 13D filing reveals substantial stock sales by 3i, LP and Tumim Stone Capital, LLC, significantly reducing their beneficial ownership in Valion Bio, Inc.

Valion Bio, Inc. is undergoing a significant leadership transition and potential capital infusion from 3i, involving the termination of its CEO and changes to its Board of Directors.

3i, LP, a significant shareholder in Valion Bio, Inc., has formally demanded the immediate removal of CEO Michael Handley, citing sustained mismanagement and destruction of shareholder value.